To further validate our data in a cellular model that mimicking well the anti-neoplastic aspects of clinical patients, we tested the efficacy of ULK1/2 blockade combined with 2-DG or 3-BP using a pancreatic patient-derived cancer cell (PDC). This evidence concerns the gene ULK1 and cancer.